Skip to main content

Publications

Selected publications

  1. Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine (Journal article - 2021)
  2. Drug interactions: a review of the unseen danger of experimental COVID-19 therapies (Journal article - 2020)
  3. Clinical Pharmacodynamics, Pharmacokinetics, and Drug Interaction Profile of Doravirine (Journal article - 2019)
  4. Prevalence of Potentially Clinically Significant Drug-Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature (Journal article - 2023)
What type of publication do you want to show?

2024

2023

Prevalence of Potentially Clinically Significant Drug-Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature

Hodge, D., Hodel, E. M., Hughes, E., Hazenberg, P., Granana Castillo, S., Gibbons, S., . . . Khoo, S. (2023). Prevalence of Potentially Clinically Significant Drug-Drug Interactions With Antiretrovirals Against HIV Over Three Decades: A Systematic Review of the Literature. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 92(2), 97-105. doi:10.1097/QAI.0000000000003122

DOI
10.1097/QAI.0000000000003122
Journal article

2022

Requests for drug-drug interaction data on direct-acting antivirals and enzyme inducing anti-epileptic agents: an overview of the HEP Interaction checker database of the University of Liverpool

Burger, D., Back, D., Martin, J., Hodge, D., Van Seyen, M., Chiong, J., . . . Marra, F. (2022). Requests for drug-drug interaction data on direct-acting antivirals and enzyme inducing anti-epileptic agents: an overview of the HEP Interaction checker database of the University of Liverpool. Journal of Hepatology, 77, S580-S581. doi:10.1016/s0168-8278(22)01481-7

DOI
10.1016/s0168-8278(22)01481-7
Journal article

Drug interactions: a review of the unseen danger of experimental COVID-19 therapies (vol 75, pg 3417, 2020)

Hodge, D., Marra, F., Marzolini, C., Boyle, A., Gibbons, S., Siccardi, M., . . . Khoo, S. (2022). Drug interactions: a review of the unseen danger of experimental COVID-19 therapies (vol 75, pg 3417, 2020). JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(7), 2050. doi:10.1093/jac/dkac111

DOI
10.1093/jac/dkac111
Journal article

2021

2020

Cellular mechanisms governing glucose-dependent insulinotropic polypeptide secretion

Reimann, F., Diakogiannaki, E., Hodge, D., & Gribble, F. M. (2020). Cellular mechanisms governing glucose-dependent insulinotropic polypeptide secretion. PEPTIDES, 125. doi:10.1016/j.peptides.2019.170206

DOI
10.1016/j.peptides.2019.170206
Journal article

2019

Chemogenetics defines receptor-mediated functions of short chain free fatty acids

Bolognini, D., Barki, N., Butcher, A. J., Hudson, B. D., Sergeevl, E., Molloy, C., . . . Milligan, G. (2019). Chemogenetics defines receptor-mediated functions of short chain free fatty acids. NATURE CHEMICAL BIOLOGY, 15(5), 489-+. doi:10.1038/s41589-019-0270-1

DOI
10.1038/s41589-019-0270-1
Journal article

Drug interaction profiles for first line antiretroviral therapy and selected fixed-dose antiretroviral combinations over 20 years of the Liverpool Drug Interaction website

Gibbons, S., Marzolini, C., Moss, C., McAllister, K., Chiong, J., Back, D., & Khoo, S. (2019). Drug interaction profiles for first line antiretroviral therapy and selected fixed-dose antiretroviral combinations over 20 years of the Liverpool Drug Interaction website. In HIV MEDICINE Vol. 20 (pp. 44-45). Retrieved from https://www.webofscience.com/

Conference Paper

2018

2016

A Novel Allosteric Activator of Free Fatty Acid 2 Receptor Displays Unique G<sub>i</sub>-functional Bias

Bolognini, D., Moss, C. E., Nilsson, K., Petersson, A. U., Donnelly, I., Sergeev, E., . . . Milligan, G. (2016). A Novel Allosteric Activator of Free Fatty Acid 2 Receptor Displays Unique G<sub>i</sub>-functional Bias. JOURNAL OF BIOLOGICAL CHEMISTRY, 291(36), 18915-18931. doi:10.1074/jbc.M116.736157

DOI
10.1074/jbc.M116.736157
Journal article

Lipid derivatives activate GPR119 and trigger GLP-1 secretion in primary murine L-cells

Hodge, D., Glass, L. L., Diakogiannaki, E., Pais, R., Lenaghan, C., Smith, D. M., . . . Reimann, F. (2016). Lipid derivatives activate GPR119 and trigger GLP-1 secretion in primary murine L-cells. PEPTIDES, 77, 16-20. doi:10.1016/j.peptides.2015.06.012

DOI
10.1016/j.peptides.2015.06.012
Journal article

The Pharmacology and Function of Receptors for Short-Chain Fatty Acids

Bolognini, D., Tobin, A. B., Milligan, G., & Moss, C. E. (2016). The Pharmacology and Function of Receptors for Short-Chain Fatty Acids. MOLECULAR PHARMACOLOGY, 89(3), 388-398. doi:10.1124/mol.115.102301

DOI
10.1124/mol.115.102301
Journal article

2012

Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodents

Moss, C. E., Marsh, W. J., Parker, H. E., Ogunnowo-Bada, E., Riches, C. H., Habib, A. M., . . . Reimann, F. (2012). Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodents. DIABETOLOGIA, 55(11), 3094-3103. doi:10.1007/s00125-012-2663-5

DOI
10.1007/s00125-012-2663-5
Journal article

Cannabinoid receptor 1 activation inhibits secretion of glucose-dependent insulinotropic polypeptide from intestinal K-cells

Moss, C. E., Marsh, W. J., Parker, H. E., Ogunnowo-Bada, E., Riches, C. H., Habib, A. M., . . . Reimann, F. (2012). Cannabinoid receptor 1 activation inhibits secretion of glucose-dependent insulinotropic polypeptide from intestinal K-cells. In DIABETOLOGIA Vol. 55 (pp. S239). Retrieved from https://www.webofscience.com/

Conference Paper

2011

Role of phosphodiesterase and adenylate cyclase isozymes in murine colonic glucagon-like peptide 1 secreting cells

Friedlander, R. S., Moss, C. E., Mace, J., Parker, H. E., Tolhurst, G., Habib, A. M., . . . Reimann, F. (2011). Role of phosphodiesterase and adenylate cyclase isozymes in murine colonic glucagon-like peptide 1 secreting cells. BRITISH JOURNAL OF PHARMACOLOGY, 163(2), 261-271. doi:10.1111/j.1476-5381.2010.01107.x

DOI
10.1111/j.1476-5381.2010.01107.x
Journal article